2010
DOI: 10.3390/cancers2041901
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Pathogenesis of Pancreatic Neuroendocrine Tumors

Abstract: Pancreatic neuroendocrine tumors (PNETs) are rare primary neoplasms of the pancreas and arise sporadically or in the context of genetically determined syndromes. Depending on hormone production and sensing, PNETs clinically manifest due to a hormone-related syndrome (functional PNET) or by symptoms related to tumor bulk effects (non-functional PNET). So far, radical surgical excision is the only therapy to cure the disease. Development of tailored non-surgical approaches has been impeded by the lack of experim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
0
0
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 49 publications
(51 reference statements)
1
0
0
1
Order By: Relevance
“…As reported previously, recurrent mutations of MEN1 and VHL are identified in distinct NET hereditary syndromes, and those involving DAXX, ATRX (found in a mutually-exclusive manner in pNETs) [30], and mTOR pathway genes (PTEN, TSC2, NF1, PIK3CA) are commonly found in sporadic PNETs [21,31,32]. In turn, in most sporadic and familial PDACs, four key driver mutations in KRAS, TP53, SMAD4, and CDKN2A, and mutations in other oncogenes (c-myc, PAK4, HER2), tumor suppressor genes (PTEN, BRCA2, PALB2, and PRSS1), and DNA mismatch repair genes (MLH1, MSH2, MSH6, and PMS2) have been found [9].…”
Section: Discussionsupporting
confidence: 68%
“…As reported previously, recurrent mutations of MEN1 and VHL are identified in distinct NET hereditary syndromes, and those involving DAXX, ATRX (found in a mutually-exclusive manner in pNETs) [30], and mTOR pathway genes (PTEN, TSC2, NF1, PIK3CA) are commonly found in sporadic PNETs [21,31,32]. In turn, in most sporadic and familial PDACs, four key driver mutations in KRAS, TP53, SMAD4, and CDKN2A, and mutations in other oncogenes (c-myc, PAK4, HER2), tumor suppressor genes (PTEN, BRCA2, PALB2, and PRSS1), and DNA mismatch repair genes (MLH1, MSH2, MSH6, and PMS2) have been found [9].…”
Section: Discussionsupporting
confidence: 68%
“…Sporadische pNEN werden in funktionell aktive (f-pNEN) und funktionell nicht aktive (nf-pNEN) Tumoren eingeteilt, wobei nf-pNEN häufiger vorkommen [28,29]. nf-pNEN werden nochmals anhand einer virtuellen Grenze bei einer Größe von 2 cm differenziert.…”
Section: Neuroendokrine Neoplasienunclassified